|
India Promises Fewer Clinical Hurdles for Biosimilars Under Some Conditions
As with its U.S. Food and Drug Administration (FDA) counterparts, Indian regulators promise fewer clinical trials for biosimilars makers who can prove their product closely matches its reference product, new guidelines state.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives